Federated Hermes, Inc. Amarin Corp Plcuk Transaction History

Federated Hermes, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$4.26 - $6.5 $14.9 Million - $22.8 Million	-3,500,000 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$3.64 - $7.76 $6.55 Million - $14 Million	-1,800,300 Reduced 33.97%	3,500,000 $14.7 Million
Q2 2020 Aug 13, 2020	BUY	$4.78 - $8.26 $8.89 Million - $15.4 Million	1,860,000 Added 54.07%	5,300,300 $36.7 Million
Q1 2020 May 13, 2020	BUY	$4.0 - $21.53 $299,588 - $1.61 Million	74,897 Added 2.23%	3,440,300 $13.8 Million
Q4 2019 Feb 14, 2020	SELL	$13.94 - $24.12 $3.04 Million - $5.25 Million	-217,777 Reduced 6.08%	3,365,403 $72.2 Million
Q3 2019 Nov 14, 2019	BUY	$13.89 - $23.16 $24.5 Million - $40.9 Million	1,765,856 Added 97.17%	3,583,180 $54.3 Million
Q2 2019 Aug 14, 2019	BUY	$16.27 - $20.51 $3.34 Million - $4.2 Million	205,000 Added 12.71%	1,817,324 $35.2 Million
Q1 2019 May 10, 2019	BUY	$12.61 - $22.33 $7.38 Million - $13.1 Million	585,000 Added 56.94%	1,612,324 $33.5 Million
Q4 2018 Feb 13, 2019	BUY	$12.41 - $22.98 $12.7 Million - $23.6 Million	1,027,295 Added 3542396.5%	1,027,324 $14 Million
Q3 2018 Nov 13, 2018	BUY	$2.45 - $16.27 $71 - $471	29 New	29 $1,000

176

65.1M

258K

98K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $254M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.